T
Thomas Metz
Researcher at Boehringer Ingelheim
Publications - 34
Citations - 746
Thomas Metz is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Bicyclic molecule & Signal transduction. The author has an hindex of 14, co-authored 34 publications receiving 746 citations. Previous affiliations of Thomas Metz include Walter and Eliza Hall Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes
TL;DR: Findings imply that p53 loss contributes directly to immortalization and tumorigenesis, probably by abrogating an intrinsic senescence program.
Patent
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
TL;DR: In this paper, the present invention relates to bicyclic heterocyclic compounds of general formula (I), wherein R a to R d, A to D and X are defined as in claims 1 to 8, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties.
Journal ArticleDOI
v-myb and v-ets transform chicken erythroid cells and cooperate both in trans and in cis to induce distinct differentiation phenotypes.
Thomas Metz,Thomas Graf +1 more
TL;DR: It is demonstrated that v-myb and v-ets can cooperate in the transformation of erythroid cells both in trans and in cis and that the mode of cooperation is reflected by the differentiation phenotypes of the transformed cells.
Patent
4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
TL;DR: In this paper, the present invention relates to bicyclic heterocycles of general formula (I), wherein Ra to Rd, A to G and X are defined as in claim 1, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases.
Patent
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
TL;DR: In this paper, the present invention relates to bicyclic heterocyclic compounds of general formula (I), wherein Ra to Rd, A to D and X are defined as in claims 1 to 8, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties.